Awards & Recognitions: Sarepta recognized for innovation and industry leadership

When your corporate mission is to engineer precision genetic medicines for rare diseases, innovation is your heartbeat. We’re honored that Sarepta and our approved gene therapy have been recognized for innovation in genetic medicine by a variety of publications and organizations.

Louise Rodino-Klapac, PhD, Executive Vice President, Chief Scientific Officer and Head of R&D, expressed her ambition for rare disease patients and Sarepta’s commitment to advancing innovation for these communities: “I feel incredibly grateful as a scientist and a researcher to do the work that I do every day to develop these medicines and bring them to patients. The great thing about working at Sarepta is how focused we are. We’re working every day for patients. We don’t back down.”

Recent honors include:

Our approved gene therapy was recognized as one of TIME’s Best Inventions of 2024 in the Medical Care Category.	Sarepta was honored with the 2024 Transformational Therapy Award by the Biotech Week Boston Awards. The award, given for our newest therapy for Duchenne muscular dystrophy, recognizes innovation in the rare disease space.	Sarepta was named winner of the Biotech Innovation category of the 2023 Fierce Life Sciences Innovation Awards.	The Cambridge Chamber of Commerce recognized Sarepta with a 2023 Visionary Award. The award celebrates the spirit of discovery and innovation that makes Cambridge unique.